Healthcare

Qiagen Weighs Stake Sale In $1 Billion Bioinformatics Arm- Bloomberg News

  • January 27, 2023 04:22 PM CET | Reuters
 Qiagen Weighs Stake Sale In $1 Billion Bioinformatics Arm- Bloomberg News

287 Jan 27 (Reuters) - * QIAGEN WEIGHS STAKE SALE IN $1 BILLION BIOINFORMATICS ARM- BLOOMBERG NEWS Source text: https://bloom.bg/3JmEh2M

Read More...

Philips Selected By Michigan Department Of Health To Provide Access To Pregnancy App

Philips Selected By Michigan Department Of Health To Provide Access To Pregnancy App

  • January 23, 2023 03:09 PM CET | Reuters

Jan 23 (Reuters) - Koninklijke Philips NV: * MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES SELECTS PHILIPS TO IMPROVE ACCESS TO VITAL RESOURCES FOR EXPECTANT MOMS THROUGH PREGNANCY+ APPLICATION

Read More...
NewAmsterdam Announces Positive Results From ROSE2, Phase 2 Trial

NewAmsterdam Announces Positive Results From ROSE2, Phase 2 Trial

  • January 17, 2023 02:41 PM CET | Reuters

Jan 17 (Reuters) - NewAmsterdam Pharma Company NV : * NEWAMSTERDAM ANNOUNCES POSITIVE RESULTS FROM ROSE2, PHASE 2 TRIAL EVALUATING OBICETRAPIB IN COMBINATION WITH EZETIMIBE AS AN ADJUNCT TO

Read More...
Philips Updates Compiled Test Results For First-Generation Dreamstation Sleep Devices

Philips Updates Compiled Test Results For First-Generation Dreamstation Sleep Devices

  • December 21, 2022 08:23 AM CET | Reuters

Dec 21 (Reuters) - Koninklijke Philips NV: * PHILIPS PROVIDES UPDATE ON COMPLETED SET OF TEST RESULTS FOR FIRST-GENERATION DREAMSTATION SLEEP THERAPY DEVICES * ADDITIONAL TEST RESULTS AND ASSESSMENTS

Read More...
Newamsterdam Pharma Company NV Announces Appointment Of David Topper As Chief Financial Officer

Newamsterdam Pharma Company NV Announces Appointment Of David Topper As Chief Financial Officer

  • December 19, 2022 10:03 PM CET | Reuters

Dec 19 (Reuters) - NewAmsterdam Pharma Company NV : * NEWAMSTERDAM ANNOUNCES APPOINTMENT OF DAVID TOPPER AS CHIEF FINANCIAL OFFICER * NEWAMSTERDAM PHARMA COMPANY NV - ANNOUNCED APPOINTMENT OF DAVID

Read More...
Pharming Announces Positive Interim Analysis Data From Leniolisib's Open-Label Extension Study

Pharming Announces Positive Interim Analysis Data From Leniolisib's Open-Label Extension Study

  • December 15, 2022 07:06 AM CET | Reuters

Dec 15 (Reuters) - Pharming Group NV: * ANNOUNCES POSITIVE INTERIM ANALYSIS DATA FROM OPEN-LABEL EXTENSION STUDY OF LENIOLISIB IN PRESENTATION AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL

Read More...
Argenx To Present Pivotal Advance Trial Data During Ash Plenary Session Highlighting Vyvgart® (Efgartigimod Alfa-Fcab) As Potential New Treatment Modality For Immune Thrombocytopenia

Argenx To Present Pivotal Advance Trial Data During Ash Plenary Session Highlighting Vyvgart® (Efgartigimod Alfa-Fcab) As Potential New Treatment Modality For Immune Thrombocytopenia

  • December 10, 2022 05:39 PM CET | Reuters

Dec 10 (Reuters) - argenx SE: * ARGENX TO PRESENT PIVOTAL ADVANCE TRIAL DATA DURING ASH PLENARY SESSION HIGHLIGHTING VYVGART® (EFGARTIGIMOD ALFA-FCAB) AS POTENTIAL NEW TREATMENT MODALITY FOR IMMUNE

Read More...
Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks

Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks

  • December 08, 2022 02:14 PM CET | Reuters

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS ANNOUNCES POSITIVE TOP-LINE PHASE 2 DATA FROM RAPIDE-1 STUDY OF PHVS416 FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS * PHARVARIS NV - PRIMARY ENDPOINT MET,

Read More...
Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update

Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update

  • December 08, 2022 02:13 PM CET | Reuters

Dec 8 (Reuters) - Pharvaris NV: * PHARVARIS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * PHARVARIS NV - EXECUTING FROM A STRONG FINANCIAL POSITION WITH CASH AND CASH

Read More...
Pharvaris NV <PHVS.O>: Losses of 25  cents announced for third quarter

Pharvaris NV <PHVS.O>: Losses of 25  cents announced for third quarter

  • December 08, 2022 01:35 PM CET | Reuters

8 December 2022 12:35 p.m. ​All figures in euros. The loss announced by Pharvaris NV in the third quarter were higher than the Refinitiv mean estimate of losses. The company reported losses of -25

Read More...
Pharvaris NV reports results for the quarter ended in September - Earnings Summary

Pharvaris NV reports results for the quarter ended in September - Earnings Summary

  • December 08, 2022 01:35 PM CET | Reuters

* Pharvaris NV reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended in September. The mean expectation of five analysts for the quarter was for a loss of 63 cents per share

Read More...